Molecular Pharmacology of Hallucinogens

  • V. S. Johnston
  • R. J. Bradley


There is as yet no satisfactory biological explanation for any of the major psychoses. However, the gap in knowledge is diminishing, and already there is a flourishing exchange of ideas and correlations between clinician and researcher. In fact, there is an ever increasing number of practising psychiatrists with active biological research interests.


Conditioned Stimulus Lever Press Amine Oxidase Lipid Solubility Conditioned Emotional Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ashcroft, G.W., Crawford, T.B.B., Eccleston, D., Sharman, D.F., MacDougall, E. J., Stanton, J.B., and Binns, J.K.: 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases, The Lancet 2:1049, 1966.CrossRefGoogle Scholar
  2. 2.
    Axelrod, J.: Metabolism of epinephrine and other sympathomimetic amines, Physiol. Rev. 39:751, 1959.PubMedGoogle Scholar
  3. 3.
    Axelrod, J.: Enzymatic formation of psychotomimetic metabolites from normally occurring compounds. Science 134:343, 1961.PubMedCrossRefGoogle Scholar
  4. 4.
    Baldessarini, R. J., and Kopin, I. J.: Assay of tissue levels of I-adenosyl-methionine, Anal. Biochem. 6:289, 1963.Google Scholar
  5. 5.
    Benington, F., Morin, R.D., and Clark, L.C. Jr.: 5-Methoxy-N,N-dimethyltryptamine, a possible endogenous psychotoxin, Ala. J. Med. Sci. 2:397, 1965.PubMedGoogle Scholar
  6. 6.
    Beriet, H.H., Bull, C., Himwich, H.E., Kohl, H., Matsumoto, K., Pscheidt, G.R., Spaide, J., Tourlentes, T.T., and Valverde, J.M.: Endogenous metabolic factor in schizophrenic behavior. Science 144:311, 1964.CrossRefGoogle Scholar
  7. 7.
    Bovet, D., and Gatti, G. L.: Analysis of the action of the psychotropic drugs in a “lever-pressing avoidance” conditioning, in: Horvath, M., and Vinar, O., Psychopharmacological Methods, Pergamon Press, Oxford, 1963. p. 50.Google Scholar
  8. 8.
    Bovet, D., and Gatti, G.L.: Analysis of parameters of the action of psycholeptic and psychomi-metic drugs in a lever-pressing avoidance conditioning, in: Bradley, P.B., Hügel, F., and Hoch, P., Neuropsychopharmacology, Elsevier, Amsterdam, 1964, p. 514.Google Scholar
  9. 9.
    Bovet, D., and Gatti, G.L.: Pharmacology of conditioning, learning and retention, in: Proceedings of 2nd International Pharmacological Meeting, Prague, 1965, p. 75.Google Scholar
  10. 10.
    Bowers, M.B., and Freedman, D. X.: “Psychedelic” experiences in acute psychoses, Arch. Gen. Psychiat. 15:240, 1966.PubMedCrossRefGoogle Scholar
  11. 11.
    Brune, G.G., and Himwich, H.E.: Indole metabolites in schizophrenic patients, Arch. Gen. Psychiat. 6:324, 1964.CrossRefGoogle Scholar
  12. 12.
    Brune, CG., and Himwich, H.E.: Effects of methionine loading on the behavior of schizophrenic patients, J. Nerv. Ment. Dis. 134:447, 1962.PubMedCrossRefGoogle Scholar
  13. 13.
    Brune, C.G., and Himwich, H.E.: Biogenic amines and behavior in schizophrenic patients, in: Wortis, J. (ed.). Recent Advances in Biological Psychiatry, Plenum Press, New York, 1963, p. 144.Google Scholar
  14. 14.
    Clark, L.C., Jr., Benington, F., and Morin, R. D.: The effects of ring-methoxy groups on biological deamination of phenethylamines, J. Med. Chem. 8:353, 1965.PubMedCrossRefGoogle Scholar
  15. 15.
    Clark, F.C., and Steele, B. J.: Some observations on the interaction of chlorpromazine and free operant avoidance bursts, Psychopharmacologia 4:221, 1963.PubMedCrossRefGoogle Scholar
  16. 16.
    De Jong, H.H.: Experimental Catatonia, Williams and Wilkins, Baltimore, 1945.Google Scholar
  17. 17.
    Estes, W.K., and Skinner, B.F.: Some quantitative aspects of anxiety, J. Exptl. Psychol. 29:390, 1941.CrossRefGoogle Scholar
  18. 18.
    Ferster, C.B., and Skinner, B.F.: Schedules of Reinforcement, Appleton Century-Crofts, New York, 1957.CrossRefGoogle Scholar
  19. 19.
    Friedhoff, A. J., and Goldstein, M.: New developments in metabolism of mescaline and related amines, Ann. N.Y. Acad. Sci. 96:5, 1962.PubMedCrossRefGoogle Scholar
  20. 20.
    Friedhoff, A. J., and Van Winkle, E.: Isolation and characterization of a compound from the urine of schizophrenics. Nature (London) 194:897, 1962.CrossRefGoogle Scholar
  21. 21.
    Gaddum, J.H.: Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine, J. Physiol. 121:1, 1953.Google Scholar
  22. 22.
    Gessner, P.K., and Page, I.H.: Behavioural effects of 5-methoxy-N,N-dimethyltryptamine, other tryptamines, and L.S.D., Am. J. Physiol. 203:167, 1962.Google Scholar
  23. 23.
    Goldwurm, G. F., and Gualandri, E.: personal communication, 1966.Google Scholar
  24. 24.
    Greiner, A.C., and Nicholson, G. A.: Schizophrenia-melanosis: Cause or side-effect?, The Lancet 1:1165, 1965.CrossRefGoogle Scholar
  25. 25.
    Guttman, E., and Maclay, W.S.: Mescaline and depersonalization, J. Neurol. Psychopath. 16:193, 1936.CrossRefGoogle Scholar
  26. 26.
    Heath, Nesselhof, W. Jr., and Timmons, E.: D,L-methionine-D,L-sulphoximine effects in schizophrenic patients, Arch. Gen. Psychiat. 14:213, 1966.PubMedCrossRefGoogle Scholar
  27. 27.
    Hollister, L.E., and Friedhoff, A. J.: Effects of 3,4-dimethoxyphenylethylamine in man, Nature (London) 210:1377, 1966.CrossRefGoogle Scholar
  28. 28.
    Holmstedt, B.: Gas-chromatographic analysis of some psychoactive indole bases, in: Himwich, H.E., Kety, S.S., and Smythies, J.R. (eds.), Amines and Schizophrenia, Pergamon Press, Atlantic City, N.J., 1967, p. 151.Google Scholar
  29. 29.
    Kety, S.S.: Proceedings of the 3rd Int. Neurochemical Symposium, Strasbourg, 1958, in: Folch-Pi, J., Chemical Pathology of the Nervous System, Pergamon Press, London, 1961, p. 709.Google Scholar
  30. 30.
    Key, B.J., and Marley, E.: Effect of some sympathomimetic amines on behaviour and electrocortical activity of chicken, Electroenceph. Clin. Neurophysiol. 14:90, 1962.PubMedCrossRefGoogle Scholar
  31. 31.
    Lai, H., Ginocchio, S., and Skefner, A.: The effect of α -methyl-3,4-dihydroxyphenylalanine (methyl-DOPA) and α -methyl-meta-tyrosine (α-MMT) on amphetamine toxicity. Life Sciences 3:190, 1963.Google Scholar
  32. 32.
    Marley, E., and Morse, W.H.: Operant conditioning in the newly hatched chicken, J. Exptl. Anal. Behav. 9:95, 1966.CrossRefGoogle Scholar
  33. 33.
    Mclsaac, W.M.: A biochemical concept of mental disease, Post-Grad. Med. 30:111, 1961.Google Scholar
  34. 34.
    Moore, K.E.: The role of endogenous norepinephrine in the toxicity of d-amphetamine in aggregated mice, J. Pharmacol. Exptl. Therap. 144:45, 1964.Google Scholar
  35. 35.
    Noteboom, L.: Experimental catatonia by means of derivatives of mescaline and adrenaline, Proc. Acad. Sci. (Amsterdam) 37:562, 1934.Google Scholar
  36. 36.
    Osmond, H., and Smythies, J.R.: Schizophrenia. Anew approach, J. Ment. Sci. 98:309, 1952.PubMedGoogle Scholar
  37. 37.
    Park, L.C., Baldessarini, R. J., and Kety, S.S.: Methionine effects on chronic schizophrenics. Arch. Gen. Psychiat. 12:346, 1965.PubMedCrossRefGoogle Scholar
  38. 38.
    Peretz, D., Smythies, J. R., and Gibson, W.C.: A new hallucinogen. Trimethoxy-phenyliso-propylamine, J. Ment. Sci. 101:317, 1955.PubMedGoogle Scholar
  39. 39.
    Pollin, W., Cardon, P.V., and Kety, S.S.: Effects of amino acid feedings in schizophrenic patients treated with iproniazid, Science 133:104, 1961.PubMedCrossRefGoogle Scholar
  40. 40.
    Quinton, R.M., and Halliwell, W.: Effects of α-methyl DOPA and DOPA on the amphetamine excitatory response in reserpinized rats, Nature (London) 200:178, 1963.CrossRefGoogle Scholar
  41. 41.
    Rosenberg, D.E., Isbell, H., and Miner, E.J.: Comparison of a placebo, N-dimethyltryp-tamine, and 6-hydroxy-N-dimethyltryptamine in man, Psychopharmacologia 4:39, 1963.PubMedCrossRefGoogle Scholar
  42. 42.
    Shulgin, A. T.: Psychotomimetic amphetamines: Methoxy 3,4-dialkoxyamphetamines, Ex-perientia 20:366, 1964.CrossRefGoogle Scholar
  43. 43.
    Shulgin, A. T.: 3-Methoxy-4,5-methylenedioxyamphetamine, a new psychotomimetic agent, Nature (London) 201:1120. 1964.CrossRefGoogle Scholar
  44. 44.
    Sidman, M.: Avoidance conditioning with brief shock and no exteroceptive warning signal, Science 118:157, 1953.PubMedCrossRefGoogle Scholar
  45. 45.
    Slotta, K. H., and Muller, J.: On the catabolism of mescaline and mescaline-like substances in the organism, Hoppe-Seyl. Z. 238:14, 1936.CrossRefGoogle Scholar
  46. 46.
    Smythies, J.R., and Levy, C.K.: The comparative psychopharmacology of some mescaline analogues, J. Ment. Sci. 106:531, 1960.PubMedGoogle Scholar
  47. 47.
    Smythies, J. R., and Sykes, E.A.: The effect of mescaline upon the conditioned avoidance response in the rat, Psychopharmacologia 6:163, 1964.PubMedCrossRefGoogle Scholar
  48. 48.
    Snyder, S.H., and Merril, C.R.: A quantum-chemical correlate of hallucinogenesis, in: Himwich, H.E., Kety, S.S., and Smythies, J.R. (eds.), Amines and Schizophrenia, Pergamon Press, Atlantic City, N, J., 1967, p. 229.Google Scholar
  49. 49.
    Steiner, J.E., and Sulman, F.G.: Simultaneous studies of blood sugar, serotonin metabolism, and electroencephalograms of the conscious rabbit after the administration of mescaline and psilocybin, Harokeach Haivri 9:498, 1963.Google Scholar
  50. 50.
    Stockings, G.T.: A clinical study of the mescaline psychosis with special reference to the mechanism of the genesis of schizophrenia and other psychotic states, J. Ment. Sci. 86:29, 1940.Google Scholar
  51. 51.
    Szara, S.: The comparison of the psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self-experiments, in: Garatani, S., and Ghetti, V. (eds.), Psychotropic Drugs, Elsevier, Amsterdam, 1957, p. 460.Google Scholar
  52. 52.
    Taborsky, R.G., Delvigs, P., and Page, I.H.: 6-Hydroxylation: Effect on the psychotropic potency of tryptamines, Science 153:1018, 1966.PubMedCrossRefGoogle Scholar
  53. 53.
    Westermann, E.O.: Metabolic factors controlling duration of drug action, in: Brodie, B.B., et al. (eds.), 1st Int. Pharm. Meeting, Pergamon Press, 1961.Google Scholar
  54. 54.
    Wikler, A.: The Relation of Psychiatry to Pharmacology, Williams and Wilkens, Baltimore, 1957.Google Scholar
  55. 55.
    Wilkinson, S.: 5-Methoxy-N-methyltryptamine: A new indole alkaloid from Phalaris arnun-dinacea, J. Chem. Soc. (London), 1958, p. 2078.Google Scholar

Copyright information

© Springer Science+Business Media New York 1968

Authors and Affiliations

  • V. S. Johnston
  • R. J. Bradley

There are no affiliations available

Personalised recommendations